Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us
  • Log out of your HL account

Evgen Pharma plc (EVG) Ordinary 0.25p

Sell:9.00p Buy:9.50p 0 Change: No change
Market closed |  Prices as at close on 8 July 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:9.00p
Buy:9.50p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 8 July 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:9.00p
Buy:9.50p
Change: No change
Market closed |  Prices as at close on 8 July 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01: breast cancer; SFX-01: subarachnoid hemorrhage, and other programs. The objective of SFX-01 therapy is to reduce the number of cancer stem cells (CSCs) proliferating in tumors treated with anti-hormonal agents and prolong the duration of response. The objective of SFX-01 therapy (co-administered with standard-of-care nimodipine) is to reduce the vasospasm and incidence of delayed cerebral ischemia in the days following the hemorrhage. It has a preclinical SFX-01 program in multiple sclerosis and a clinical interest in prostate cancer.

Contact details

Address:
The Colony
146 Brownlow Hill, Altrincham Road
WILMSLOW
SK9 4LY
United Kingdom
Telephone:
+44 (0151) 7053532
Website:
evgen.com/

Important dates

Future events
AGM 16 July 2020 16/07/20
Past events
Final results 15 June 2020 15/06/20
Interim results 17 December 2019 17/12/19
AGM 18 July 2019 18/07/19

General stock information

EPIC:
EVG
ISIN:
GB00BSVYN304
Market cap:
£12.27 million
Shares in issue:
132.65 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Barry Clare
    Executive Chairman of the Board
  • Richard Moulson
    Chief Financial Officer, Director
  • Hamina Patel
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.